- Home
- GENC vs INBX Comparison
GENC vs INBX Comparison
Compare GENC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- INBX
- Stock Information
- Founded
- GENC 1894
- INBX 2010
- Country
- GENC United States
- INBX United States
- Employees
- GENC N/A
- INBX N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- INBX Health Care
- Exchange
- GENC Nasdaq
- INBX Nasdaq
- Market Cap
- GENC 211.1M
- INBX 178.5M
- IPO Year
- GENC N/A
- INBX 2020
- Fundamental
- Price
- GENC $14.12
- INBX $15.69
- Analyst Decision
- GENC
- INBX Hold
- Analyst Count
- GENC 0
- INBX 1
- Target Price
- GENC N/A
- INBX N/A
- AVG Volume (30 Days)
- GENC 18.7K
- INBX 71.4K
- Earning Date
- GENC 08-08-2025
- INBX 08-12-2025
- Dividend Yield
- GENC N/A
- INBX N/A
- EPS Growth
- GENC 35.02
- INBX N/A
- EPS
- GENC 1.11
- INBX 111.58
- Revenue
- GENC $113,116,000.00
- INBX $200,000.00
- Revenue This Year
- GENC N/A
- INBX N/A
- Revenue Next Year
- GENC N/A
- INBX N/A
- P/E Ratio
- GENC $12.73
- INBX $0.13
- Revenue Growth
- GENC 5.44
- INBX N/A
- 52 Week Low
- GENC $10.80
- INBX $10.80
- 52 Week High
- GENC $24.88
- INBX $17.79
- Technical
- Relative Strength Index (RSI)
- GENC 52.65
- INBX 66.26
- Support Level
- GENC $13.81
- INBX $14.19
- Resistance Level
- GENC $14.77
- INBX $15.67
- Average True Range (ATR)
- GENC 0.48
- INBX 0.84
- MACD
- GENC -0.04
- INBX 0.13
- Stochastic Oscillator
- GENC 54.48
- INBX 96.27
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.